- Home
- PETS vs NRXP Comparison
PETS vs NRXP Comparison
Compare PETS & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- NRXP
- Stock Information
- Founded
- PETS 1996
- NRXP 2015
- Country
- PETS United States
- NRXP United States
- Employees
- PETS N/A
- NRXP N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- PETS Consumer Staples
- NRXP Health Care
- Exchange
- PETS Nasdaq
- NRXP Nasdaq
- Market Cap
- PETS 50.0M
- NRXP 58.5M
- IPO Year
- PETS N/A
- NRXP N/A
- Fundamental
- Price
- PETS $2.62
- NRXP $3.18
- Analyst Decision
- PETS Sell
- NRXP Strong Buy
- Analyst Count
- PETS 1
- NRXP 5
- Target Price
- PETS $3.20
- NRXP $31.40
- AVG Volume (30 Days)
- PETS 90.5K
- NRXP 461.1K
- Earning Date
- PETS 10-14-2025
- NRXP 11-13-2025
- Dividend Yield
- PETS N/A
- NRXP N/A
- EPS Growth
- PETS N/A
- NRXP N/A
- EPS
- PETS N/A
- NRXP N/A
- Revenue
- PETS $226,972,000.00
- NRXP N/A
- Revenue This Year
- PETS N/A
- NRXP N/A
- Revenue Next Year
- PETS $2.98
- NRXP $395.09
- P/E Ratio
- PETS N/A
- NRXP N/A
- Revenue Growth
- PETS N/A
- NRXP N/A
- 52 Week Low
- PETS $2.42
- NRXP $1.12
- 52 Week High
- PETS $6.85
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- PETS 50.52
- NRXP 52.51
- Support Level
- PETS $2.46
- NRXP $2.95
- Resistance Level
- PETS $2.68
- NRXP $3.19
- Average True Range (ATR)
- PETS 0.11
- NRXP 0.24
- MACD
- PETS 0.02
- NRXP -0.03
- Stochastic Oscillator
- PETS 84.31
- NRXP 30.34
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.